The Indian Pharma Industry under the Product Patent Regime
|
|
ICMR HOME | Case Studies Collection
To download The Indian Pharma Industry under the Product Patent Regime case study
(Case Code: BSTR169) click on the button below, and select the case from the list of available cases:
OR
Buy With PayPal
|
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Case Details: |
Price: |
| Case Code |
: |
BSTR169 |
Electronic Format: Rs.
700;
Courier (within India):Rs. 25 Extra
Themes- |
| Case Length |
: |
26 Pages |
| Period |
: |
1990-2005 |
| Organization |
: |
- |
| Pub Date |
: |
2005 |
| Teaching Note |
: |
Not Available |
| Countries
|
: |
India |
| Industry |
: |
Pharmaceutical |
Abstract:
|
The Indian pharma industry has been consistently charting high growth rate in
the 1990s and 2000s. The industry which was controlled by the government in the
1970s and 1980s to ensure that medicines were sold at affordable prices, has
slowly been liberalised in the 1990s and 2000s. The note explains India's
evolution as a pharma supplier to the world, and how India moved into a product
patent regime from a process patent regime, in order to comply with its
international obligations as part of the WTO agreement on TRIPS. The note
explains the role played by the government in facilitating the growth of the
industry, the regulatory regime that existed in India prior to liberalisation,
the export orientation of the industry, the major pharma players in the country,
and issues affecting the industry etc.
|
|
The note ends with an optimistic outlook
stating that the Indian pharma industry will soon be an R&D hub
for multinationals in custom research and clinical trials and
the industry has the potential to tap the growing generics
market in Europe and the US.
Issues:
» Effect of multilateral trade agreements on an industry
» Moving up the value chain
» Role of government in facilitating the growth of an industry
Contents:
Keywords:
Indian Pharma Industry, Product patent, Process Patent, DPCO,
FERA, Small Scale Industry, TRIPS, The Indian Patent Act, World Trade
Organization, Exclusive Marketing Rights (EMR), Union Budget 2005-06, Wockhardt
Ltd., Value Added Tax (VAT), Ranbaxy Laboratories Ltd., Dr. Reddy's Laboratories
Limited, Patent Regime, Pharma Industry, Bulk Drugs, Pharmaceutical Industry, Exchange Regulated Act, Foreign Exchange, Domestic Market, Patent Act, Clinical Research, Leading Pharma Companies
The Indian Pharma Industry under the Product Patent Regime
- Next Page>>
|
|
